{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:57:27Z","timestamp":1765886247297,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.hlc.2020.10.012","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:55:45Z","timestamp":1605257745000},"page":"683-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Dan","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunkang","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2020.10.012_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2020.10.012_bib2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.798","article-title":"Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)","volume":"19","author":"Rickenbacher","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2020.10.012_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2020.10.012_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2013.10.006","article-title":"Developing therapies for heart failure with preserved ejection fraction: current state and future directions","volume":"2","author":"Butler","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hlc.2020.10.012_bib5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle","volume":"350","author":"Zile","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2020.10.012_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","article-title":"Impaired systolic function by strain imaging in heart failure with preserved ejection fraction","volume":"63","author":"Kraigher-Krainer","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2020.10.012_bib7","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jacc.2011.07.042","article-title":"Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction","volume":"58","author":"McKie","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2020.10.012_bib8","doi-asserted-by":"crossref","first-page":"e002727","DOI":"10.1161\/CIRCHEARTFAILURE.115.002727","article-title":"Developing new treatments for heart failure: focus on the heart","volume":"9","author":"Gheorghiade","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hlc.2020.10.012_bib9","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2020.10.012_bib10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2020.10.012_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition - implications for arnis","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hlc.2020.10.012_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2020.10.012_bib13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor lcz696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2020.10.012_bib14","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2020.10.012_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.hlc.2020.10.012_bib16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2020.10.012_bib17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.hlc.2016.11.024","article-title":"Preoperative statin treatment for the prevention of acute kidney injury in patients undergoing cardiac surgery: a meta-analysis of randomised controlled trials","volume":"26","author":"Xiong","year":"2017","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2020.10.012_bib18","first-page":"140","article-title":"Comparative efficacy of renin-angiotensin aldesteron system modulators and angiotensin receptor neprilyzin inhibitor in chronic heart failure with mid-ranged and preserved ejection fraction","volume":"21","author":"Tumasyan","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2020.10.012_bib19","first-page":"176","article-title":"The effect of sacubitril\u2013valsartan for the treatment of heart failure patients with mid-range ejection fraction","volume":"31","author":"Wang","year":"2019","journal-title":"Strait Pharmaceutical J"},{"key":"10.1016\/j.hlc.2020.10.012_bib20","first-page":"83","article-title":"Curative effect of sakubitril-valsartan on heart failure with preserved ejection fraction","volume":"12","author":"Shi","year":"2020","journal-title":"Chin J Evid-Based Cardiovasc Med"},{"key":"10.1016\/j.hlc.2020.10.012_bib21","first-page":"88","article-title":"Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with midrange ejection fraction","volume":"39","author":"Chen","year":"2020","journal-title":"Chin J New Drugs Clin Rem"},{"key":"10.1016\/j.hlc.2020.10.012_bib22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the charm-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2020.10.012_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.HYP.0000258532.07418.fa","article-title":"Molecular biology of the natriuretic peptide system: implications for physiology and hypertension","volume":"49","author":"Gardner","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2020.10.012_bib24","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2020.10.012_bib25","doi-asserted-by":"crossref","first-page":"e17296","DOI":"10.1097\/MD.0000000000017296","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40","volume":"98","author":"Zhao","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.hlc.2020.10.012_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2010.10.005","article-title":"Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure","volume":"17","author":"Chow","year":"2011","journal-title":"J\u00a0Card Fail"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062031475X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062031475X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:03:06Z","timestamp":1761415386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S144395062031475X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S144395062031475X"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2020.10.012","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2020.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}